The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

07 Jul 2020 | Press release

QC-validated cell lines optimized to work alongside Horizon’s Edit-R predesigned sgRNA products and DharmaFECT transfection reagents

 

Cambridge, UK, 07 July 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively. The cell lines are optimized to work alongside Horizon’s Edit-R predesigned synthetic single guide RNA (sgRNA) and CRISPRa guide RNA, offering researchers a complete solution to simplify and streamline CRISPR gene editing and modulation workflows.

Horizon’s Cas9 and dCas9-VPR stable cell lines were generated using its Edit-R Lentiviral particles with a blasticidin resistance cassette and are provided in pooled format. The cell lines are QC verified and validated to ensure stable expression and functionality of Cas9 or dCas9-VPR endonuclease in a range of common cell backgrounds. Both cell lines are available in the same background to enable loss- and gain-of-function studies to be performed in parallel, without the need to engineer a cell line specifically for this purpose. Removing the time-intensive step of generating a stable cell line and the cost associated with purchasing a nuclease could help researchers increase R&D productivity and allow novice users gain a better understanding of the CRISPR workflow.

Travis Hardcastle, Product Manager, Horizon Discovery, said:These stable Cas9 cell lines demonstrate our commitment to making gene editing more accessible and provide the added benefit of decreasing the demand on researchers time, expediting basic research to the target identification and validation phase of the drug discovery pipeline.
Horizon is currently one of the only suppliers to offer a stable dCas9-VPR cell line for CRISPR activation and gain-of-function studies as well as the whole gene editing solution including a stable cell line, guide RNA and transfection reagent, allowing researchers to obtain the cells and reagents for both CRISPR knockout and activation studies from the same source.

To introduce the range, Horizon is offering a launch bundle which will include one stable cell line background with a set of three predesigned synthetic sgRNAs and choice of DharmaFECT transfection reagent.

For further information on Horizon’s Cas9 and dCas9-VPR stable cell lines, please visit: https://horizondiscovery.com/en/navigation/gene-editing/cell-models/Cas9-stable-cell-lines

ENDS

 

For high res images please contact lorna.cuddon@zymecommunications.com

 microscope image of Horizon Cas9 stable cells    Travis Hardcastle Product Manager for Horizon Discovery
 Horizon Discovery's Cas9 stable cells        Travis Hardcastle, Product Manager, Horizon Discovery

 

For further information from Horizon Discovery Group plc, please contact:


Zyme Communications (Trade and Regional Media)
Lorna Cuddon
Tel: +44 (0)7811 996 942
Email: lorna.cuddon@zymecommunications.com  

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

About Horizon Discovery Group plc - horizondiscovery.com

 

Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows. 

Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines. 

The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the Company to focus efforts on development of innovative solutions that not only differentiate the Company’s offering, but also fuel development of the next wave of precision medicines.

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

Follow Horizon Discovery on Twitter @HZDiscovery and LinkedIn @Horizon Discovery